Developing new oral antibiotics to treat resistant bacterial infections
Official title: New oral antibiotics focused on treating MDR Gram-negative infections
Funded at Curza INC · NIH-11007661 · Data updated 2026-11-12
This study is working on a new type of antibiotic that can help treat tough infections caused by bacteria that don't respond to many current medicines, aiming to create a safe and effective pill for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curza INC NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project start | July 9, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 1R44AI186898-01 |
| Project ID | NIH-11007661 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant Gram-negative bacteria.
✕Less likely to help
Patients with infections caused by non-Gram-negative bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on creating a new class of antibiotics specifically designed to combat multidrug-resistant (MDR) Gram-negative bacteria. The approach involves developing inhibitors that target a unique site on the bacterial ribosome, which is not affected by existing antibiotics, thereby reducing the risk of cross-resistance. The antibiotics are inspired by natural products but have been engineered to enhance their effectiveness and safety for patients. The goal is to produce a potent, orally administered antibiotic that can effectively treat serious infections caused by resistant bacteria.
Why it matters
Potential benefit: If successful, this research could provide patients with new treatment options for infections that are currently difficult to manage due to antibiotic resistance.
How similar studies have gone: Other research has shown promise in developing antibiotics targeting unique bacterial ribosome sites, indicating potential for success in this novel approach.
Where this research is happening
-
Curza INC
Salt Lake City, United States Active
Researchers
- Principal investigator: Testa, Charles — Curza INC
- Study coordinator: Testa, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.